MX2024007731A - Formulaciones del factor i del complemento. - Google Patents
Formulaciones del factor i del complemento.Info
- Publication number
- MX2024007731A MX2024007731A MX2024007731A MX2024007731A MX2024007731A MX 2024007731 A MX2024007731 A MX 2024007731A MX 2024007731 A MX2024007731 A MX 2024007731A MX 2024007731 A MX2024007731 A MX 2024007731A MX 2024007731 A MX2024007731 A MX 2024007731A
- Authority
- MX
- Mexico
- Prior art keywords
- formulations
- cfi
- complement factor
- wild
- variants
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 5
- 102000003689 Complement Factor I Human genes 0.000 title 1
- 108090000044 Complement Factor I Proteins 0.000 title 1
- 230000004927 fusion Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000008100 Human Serum Albumin Human genes 0.000 abstract 1
- 108091006905 Human Serum Albumin Proteins 0.000 abstract 1
- 230000037328 acute stress Effects 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21045—Complement factor I (3.4.21.45)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163293013P | 2021-12-22 | 2021-12-22 | |
| PCT/US2022/082179 WO2023122691A1 (en) | 2021-12-22 | 2022-12-21 | Complement factor-i formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024007731A true MX2024007731A (es) | 2024-07-01 |
Family
ID=85172701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024007731A MX2024007731A (es) | 2021-12-22 | 2022-12-21 | Formulaciones del factor i del complemento. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250009855A1 (enExample) |
| EP (1) | EP4452321A1 (enExample) |
| JP (1) | JP2025503483A (enExample) |
| KR (1) | KR20240124950A (enExample) |
| CN (1) | CN118450906A (enExample) |
| AU (1) | AU2022420007A1 (enExample) |
| CA (1) | CA3241714A1 (enExample) |
| IL (1) | IL313777A (enExample) |
| MX (1) | MX2024007731A (enExample) |
| WO (1) | WO2023122691A1 (enExample) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201821082D0 (en) * | 2018-12-21 | 2019-02-06 | Gyroscope Therapeutics Ltd | Combination of complement factors i and h, and vector encoding thereof |
| WO2021081348A1 (en) * | 2019-10-23 | 2021-04-29 | Gemini Therapeutics Inc. | Methods for treating patients having cfi mutations with recombinant cfi proteins |
| CA3182800A1 (en) * | 2020-06-14 | 2021-12-23 | Vertex Pharmaceuticals Inc. | Complement factor i-related compositions and methods |
-
2022
- 2022-12-21 IL IL313777A patent/IL313777A/en unknown
- 2022-12-21 EP EP22854364.1A patent/EP4452321A1/en active Pending
- 2022-12-21 WO PCT/US2022/082179 patent/WO2023122691A1/en not_active Ceased
- 2022-12-21 CA CA3241714A patent/CA3241714A1/en active Pending
- 2022-12-21 MX MX2024007731A patent/MX2024007731A/es unknown
- 2022-12-21 JP JP2024537890A patent/JP2025503483A/ja active Pending
- 2022-12-21 AU AU2022420007A patent/AU2022420007A1/en active Pending
- 2022-12-21 KR KR1020247022975A patent/KR20240124950A/ko active Pending
- 2022-12-21 CN CN202280084962.2A patent/CN118450906A/zh active Pending
-
2024
- 2024-06-21 US US18/750,927 patent/US20250009855A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022420007A1 (en) | 2024-06-20 |
| WO2023122691A1 (en) | 2023-06-29 |
| EP4452321A1 (en) | 2024-10-30 |
| IL313777A (en) | 2024-08-01 |
| JP2025503483A (ja) | 2025-02-04 |
| US20250009855A1 (en) | 2025-01-09 |
| CN118450906A (zh) | 2024-08-06 |
| KR20240124950A (ko) | 2024-08-19 |
| CA3241714A1 (en) | 2023-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Leong et al. | Amoeboid and ramified microglia: their interrelationship and response to brain injury | |
| CL2021001957A1 (es) | Formulaciones que contienen proteína de fusión del receptor de vegf a alta concentración. (divisional solicitud 202002872) | |
| CO2022002864A2 (es) | Administración de vectores de virus adenoasociado de alfa-sarcoglicano y el tratamiento de la distrofia muscular | |
| ES2109899T1 (es) | Metodo, composiciones y kits para aumentar la biodisponibilidad oral de agentes farmaceuticos. | |
| ES2083876T3 (es) | Cateter para inyectar medicamentos. | |
| ES2160485B1 (es) | Peptidos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen. | |
| ES2023095T3 (es) | Cateter con zona en forma globular. | |
| ES2092702T3 (es) | Cateter con balon separable para tratamiento endoscopico. | |
| DE602006016058D1 (de) | Vorrichtungen zur Behandlung von empfänglicher Plaque | |
| RU2002107319A (ru) | Уменьшение объема ткани | |
| Myung et al. | Platelet‐rich plasma improves the therapeutic efficacy of mesenchymal stem cells by enhancing their secretion of angiogenic factors in a combined radiation and wound injury model | |
| ES2182899T3 (es) | Formulacion farmaceutica para la administracion subcutanea, intramuscular o intradermica de factor viii. | |
| MX2021007241A (es) | Acido ribonucleico (arn) que codifica para una proteina. | |
| MX2019006515A (es) | Composiciones que comprenden peptido wkdeagkplvk. | |
| ES2093122T3 (es) | Activacion mejorada de proteinas recombinantes. | |
| MX2024007731A (es) | Formulaciones del factor i del complemento. | |
| ES2527664T3 (es) | Tratamiento de la cistitis intersticial con una dosis alta de sulfato de condroitina | |
| AR110031A1 (es) | Métodos de tratamiento de pacientes con cáncer con inhibidores de farnesiltransferasa | |
| AR128464A1 (es) | Péptidos agonistas duales glp-1 y glucagón con estabilidad biológica mejorada | |
| ES2119165T3 (es) | Nueva actividad de cofactor anticoagulante. | |
| CN105999527A (zh) | 鼻腔给药装置 | |
| CN205107828U (zh) | 肿瘤内科多功能介入治疗针 | |
| CN104288780A (zh) | Gfp-30蛋白质和脂质体于制备治疗感音神经性耳聋或遗传性耳聋蛋白质药物中的应用 | |
| CN205494635U (zh) | 一种新型用于体外膜肺氧合器官保护的双腔动脉灌注导管 | |
| ES1137507U (es) | Dispositivo para inmovilización de tubos de administración de oxígeno en pacientes anestesiados. |